Trial Profile
A multi-center, randomized, double-blind, placebo-controlled study of DITPA in patients with NYHA [New York Heart Association] class III and IV congestive heart failure who have low serum T3 [liothyronine] levels
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs DITPA (Primary)
- Indications Heart failure
- Focus Adverse reactions
- 14 Nov 2006 Status change
- 20 Oct 2005 New trial record.